Melanoma Institute Australia welcomes new CEO Matthew Browne

Melanoma Institute Australia welcomes new CEO Matthew Browne

9 August 2018

Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).

Matthew, who takes up the position effective immediately, brings to the organisation a wealth of experience in managing organisations involved in health care and major infrastructure projects.

He has been with Melanoma Institute Australia since January 2017, having performed the roles of Chief Financial Officer and Company Secretary, and more recently Acting CEO. Prior to joining Melanoma Institute Australia, Matthew was Acting CEO for Cure Brain Cancer Foundation and held a variety of senior executive roles responsible for Transport NSW’s Opal smartcard ticketing project, including  Director of Ticketing.

Matthew holds a Bachelor of Economics from Macquarie University and has been a member of the Institute of Chartered Accountants in Australia since 1990.

Chairman of Melanoma Institute Australia, Mr Grant King said; “We are excited to welcome Matthew as CEO of Melanoma Institute Australia as his leadership skills and experience in the medical research and not for profit sectors will ensure the organisation continues to be a world leader in melanoma prevention, treatment and cure.”

“Given Matthew’s previous executive roles, including at Melanoma Institute Australia, we are confident his transition into the CEO role will be smooth and effective and the organisation will continue its momentum towards its mission of zero deaths from melanoma,” he said.

“I am delighted and honoured to be leading such a world-class organisation,” Matthew Browne said. “I am proud of the achievements made by Melanoma Institute Australia over many years, providing patients with melanoma the very best standard of care and more life-saving treatment options.

“Melanoma Institute Australia is deeply committed to achieving its mission, and it will truly be a time to celebrate when that day arrives,” he said.

For more information, please contact:

Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | jennifer.durante@melanoma.org.au

The latest research from Dr James Wilmott

The latest research from Dr James Wilmott

Dr James Wilmott is researching how melanoma forms in young people.

Jay Allen MIA's Community Coordinator nominated for NSW Australian of the Year award

Jay Allen MIA's Community Coordinator nominated for NSW Australian of the Year award

Congratulations to MIA’s Community Coordinator and melanoma survivor Jay Allen who has been announced as a nominee for the 2018  Australian of the Year Awards.

First patient recruited to the EAGLE FM Trial

First patient recruited to the EAGLE FM Trial

Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.